$30,000 of ARDELYX INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues."
You can find more data on corporate lobbying on Quiver Quantitative.
ARDX Insider Trading Activity
ARDX insiders have traded $ARDX stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $ARDX stock by insiders over the last 6 months:
- LAURA A WILLIAMS (Chief Patient Officer) has made 0 purchases and 5 sales selling 142,687 shares for an estimated $911,298.
- MICHAEL RAAB (President & CEO) has made 0 purchases and 2 sales selling 92,574 shares for an estimated $530,610.
- ERIC DUANE FOSTER (Chief Commercial Officer) has made 0 purchases and 2 sales selling 21,122 shares for an estimated $122,994.
- ELIZABETH A GRAMMER (See Remarks) has made 0 purchases and 2 sales selling 11,836 shares for an estimated $67,840.
- MIKE KELLIHER (See Remarks) has made 0 purchases and 2 sales selling 10,977 shares for an estimated $62,917.
- JOSEPH JAMES REILLY (See Remarks) sold 11,086 shares for an estimated $61,382
- JUSTIN A RENZ (Chief Financial Officer) sold 7,037 shares for an estimated $41,741
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARDX Hedge Fund Activity
We have seen 115 institutional investors add shares of ARDX stock to their portfolio, and 92 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 4,021,242 shares (-34.5%) from their portfolio in Q3 2025, for an estimated $22,157,043
- BANK OF AMERICA CORP /DE/ removed 2,873,791 shares (-52.0%) from their portfolio in Q3 2025, for an estimated $15,834,588
- VANGUARD GROUP INC added 2,337,672 shares (+14.6%) to their portfolio in Q3 2025, for an estimated $12,880,572
- MARSHALL WACE, LLP removed 2,307,610 shares (-20.5%) from their portfolio in Q3 2025, for an estimated $12,714,931
- NUVEEN, LLC added 1,685,009 shares (+48.3%) to their portfolio in Q3 2025, for an estimated $9,284,399
- TWO SEAS CAPITAL LP removed 1,539,416 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,482,182
- EVERSEPT PARTNERS, LP added 1,429,377 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7,875,867
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARDX Analyst Ratings
Wall Street analysts have issued reports on $ARDX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 01/09/2026
- Citigroup issued a "Buy" rating on 11/03/2025
- TD Cowen issued a "Buy" rating on 10/31/2025
To track analyst ratings and price targets for ARDX, check out Quiver Quantitative's $ARDX forecast page.
ARDX Price Targets
Multiple analysts have issued price targets for $ARDX recently. We have seen 6 analysts offer price targets for $ARDX in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $14.0 on 01/09/2026
- Julian Harrison from BTIG set a target price of $17.0 on 01/09/2026
- Christopher Raymond from Piper Sandler set a target price of $16.0 on 01/09/2026
- Joseph Thome from TD Cowen set a target price of $10.0 on 10/31/2025
- Laura Chico from Wedbush set a target price of $14.0 on 08/05/2025
- Ryan Deschner from Raymond James set a target price of $12.0 on 08/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
